Recent Updates
Recently added Catalysts

ACT-064992

Phase 2

Idiopathic Pulmonary Fibrosis | Small molecule | Respiratory |Johnson & Johnson|Last Updated: Feb 17, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment178
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00903331Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical StudyPHASE2 COMPLETED 178May 1, 2009Aug 1, 2011Feb 17, 201453 United States, Australia +10
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Forced Vital Capacity (FVC) at Baseline and End of Period 1
12 months

FVC was measured at baseline and at the end of Period 1. The same equipment and tester were used during the course of the study. The equipment was calibrated and the calibration documented prior to each patient's measurement. The person responsible for conducting the pulmonary function tests was required to comply with the study guidelines and the American Thoracic Society/European Respiratory Society joint criteria on lung function testing.

Secondary Endpoints
Number of Patients at Risk of Event of Disease Worsening or Death up to the End of Study
Up to end of study (Up to 24 months)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ACT-064922EXPERIMENTALACT-064922 tablet (macitentan), 10 mg, once daily
PlaceboPLACEBO_COMPARATORMatching placebo, once daily
Interventions
NameTypeDescription
ACT-064992 (macitentan)DRUGACT-064992 (macitentan) tablet, 10 mg, once daily
PlaceboDRUGmatching placebo, once daily
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites53

Inclusion Criteria: 1. Signed informed consent. 2. Male or female patients of at least 18 years of age (females of child-bearing potential must use a reliable method of contraception). 3. IPF diagnosis within 3 years prior to randomization, proven according to the American Thoracic Society/European...

Countries:United StatesAustraliaCanadaFranceGermanyIsraelItalySloveniaSouth AfricaSpainSwedenTurkey (Türkiye)
Unlock Eligibility Criteria